Consistently, a study confirmed that enzymes including CYP1A1, CYP2C19, ABCB1, and other key transporters involved in drug resistance were significantly upregulated in the anthracycline-R breast cancer cell lines [34,35,36]. Here, CYP2C19 is linked to breast carcinoma.